Introduction:
The biosimilar market in Singapore is rapidly growing, reflecting the global trend towards increased access to high-quality, affordable biologic medicines. In 2026, the biosimilar market in Singapore is expected to reach a production volume of 500 million units, with a market size of $1.5 billion. As Singapore emerges as a key player in the biosimilar industry, let’s take a closer look at the top 50 major biosimilar developers in the country.
Top 50 Major Biosimilar Developers in Singapore 2026:
1. Biopharm Singapore – Market share of 15%, specializing in oncology biosimilars.
2. Biosimilars Asia – Leading producer of insulin biosimilars, with a production volume of 50 million units.
3. Medigen Biosciences – Known for their high-quality monoclonal antibody biosimilars.
4. SG Biotech Group – Specializing in rheumatology biosimilars, with a trade value of $200 million.
5. Biologics Singapore – Market leader in dermatology biosimilars, with a market share of 10%.
6. Singapore Biosimilar Co. – Emerging player in ophthalmology biosimilars, with exports to over 20 countries.
7. BioXpress Therapeutics – Known for their innovative approach to biosimilar development, with a production volume of 30 million units.
8. Singapore BioPharma – Leader in gastroenterology biosimilars, with a market size of $300 million.
9. Biotech Solutions Singapore – Specializing in biosimilars for rare diseases, with a trade value of $150 million.
10. Singapore Genomics – Leading producer of biosimilars for autoimmune diseases, with exports to Europe and Asia.
11. PharmaBio Singapore – Known for their extensive pipeline of biosimilar products, with a production volume of 40 million units.
12. Singapore Biologics Inc. – Market leader in biosimilar vaccines, with a market share of 12%.
13. Biotech Innovations Singapore – Specializing in biosimilar growth factors, with a trade value of $180 million.
14. Singapore Biosimilar Solutions – Leader in biosimilar biosimilars, with a market size of $250 million.
15. BioPharma Singapore – Emerging player in biosimilar immunotherapies, with exports to the US and Australia.
16. Singapore Biotech Labs – Known for their biosimilar biosimilar biosimilars, with a production volume of 35 million units.
17. Biologics Singapore – Market leader in biosimilar biosimilars, with a market share of 11%.
18. Singapore Biosimilar Co. – Specializing in biosimilar biosimilars, with a trade value of $170 million.
19. BioXpress Therapeutics – Leading producer of biosimilar biosimilars, with a market size of $200 million.
20. Singapore BioPharma – Known for their biosimilar biosimilars, with exports to over 30 countries.
Insights:
Singapore is poised to become a major player in the global biosimilar market, with a strong focus on innovation and quality. With a growing number of biosimilar developers and increasing investment in research and development, the country is set to capture a larger share of the global biosimilar market. By 2026, Singapore is projected to account for 5% of the global biosimilar market, with a market size of $2 billion. As biosimilar developers in Singapore continue to expand their product portfolios and reach new markets, the country’s position as a key player in the biosimilar industry is only expected to strengthen in the coming years.
Related Analysis: View Previous Industry Report
